The prognostic significance of minimal residual disease (MRD) in patients with multiple myeloma has been examined in numerous studies and is the subject of much controversial discussion. Existing data has to date been extremely heterogeneous with regard to patient collectives, therapies, number of cases, and the methodology via which MRD was detected. However, since the presentation of the meta-analysis by Munshi et al. (JAMA 2017), it can be considered as proven that MRD negativity after first-line therapy is one of the strongest surrogate markers for prolonged overall survival.

Since 2009, MLL has been accredited according to the international standards DIN EN ISO 15189 "Medical laboratories - Requirements for quality and competence" and DIN EN ISO/IEC 17025 "General requirements for the competence of testing and calibration laboratories" by the Deutsche Akkreditierungsstelle (DAkkS). In April this year, MLL was once again audited by DAkkS. Its existing accreditations were successfully upheld and expanded with new analyses.